• Sign In
  • Sign Out
  • My Account
Subscribe
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
  • Special reports
Clarivate
  • Data Snapshots
  • BioWorld
  • BioWorld MedTech
  • Infographics: Dynamic digital data analysis
  • Special reports
  • Infographics: Dynamic digital data analysis
  • Trump administration impacts
  • Biopharma M&A scorecard
  • BioWorld 2024 review
  • BioWorld MedTech 2024 review
  • BioWorld Science 2024 review
  • Women's health
  • China's GLP-1 landscape
  • PFA re-energizes afib market
  • China CAR T
  • Alzheimer's disease
  • Israel
  • Rise of obesity
  • Radiopharmaceuticals
  • Biosimilars
  • Aging
  • IVDs on the rise
  • Coronavirus
  • Artificial intelligence

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
Home » Newsletters » BioWorld

BioWorld

July 3, 2017

View Archived Issues

Holiday notice

The offices of BioWorld will be closed in observance of the Independence Day holiday in the U.S. Read More

Financings

Clementia Pharmaceutical Inc., of Montreal, filed its F-1 with the SEC to raise up to $115 million in an IPO. The company is developing lead compound palovarotene, a retinoic acid receptor gamma agonist, to treat fibrodysplasia ossificans progressiva (FOP) and multiple osteochondroma (MO). Read More

Other news to note

Theratechnologies Inc., of Montreal, said it was notified by partner Taimed Biologics Inc., of Taipei, Taiwan, that the FDA accepted for review the BLA for ibalizumab as a treatment for multidrug-resistant HIV-1. Read More

In the clinic

Boston Biomedical Inc., of Cambridge, Mass., reported data from a phase Ib/II trial testing napabucasin in metastatic colorectal cancer (mCRC) and pancreatic adenocarcinoma (mPDAC) at the European Society of Medical Oncology 19th World Congress on Gastrointestinal Cancer in Barcelona, Spain. Read More

Australia rolls out new priority review, orphan drug pathways

PERTH, Australia – Australia's Therapeutic Goods Administration (TGA) will start accepting priority review applications, and it has expanded its orphan drug designation criteria, thanks to new legislation passed earlier this month that overhauls the country's drug regulations. Read More

Indi raises $11.5M in series A round to back new synthetic class in molecular imaging

Indi Molecular has an impressive pedigree, having been founded in 2013 by Leroy Hood of the Institute of Systems Biology, James Heath of Caltech and diagnostics entrepreneur Albert Luderer. It's a spinout from parent company Integrated Diagnostics that was first seeded with $1.8 million from Interwest Partners, Asset Management Ventures and angel investors. Read More

Amgen's Vectibix wins expanded FDA nod with multigene CDx

Illumina Inc. is set to provide its sequencing cancer companion diagnostic test kit to be used along with Amgen Inc.'s EGFR-targeting drug, Vectibix (panitumumab), which earned a supplemental approval for use as a first-line treatment in wild-type RAS metastatic colorectal cancer patients in combination with FOLFOX and as a monotherapy following disease progression after prior treatment with fluoropyrimidine, oxaliplatin and irinotecan-containing chemotherapy. Read More

Given due weight: Result in Alkermes bid satisfies, to 'Enlighten' more later

Efficacy against acute exacerbations of schizophrenia looks strong in top-line phase III data from the four-week Enlighten-1 trial with Alkermes plc's ALKS-3831, but the world won't know until next year about the weight gain and metabolic aspects investigated by a six-month experiment called Enlighten-2. Read More

Despite hip win, Cara investors wince at oral CR-845 findings in chronic OA pain

"This is why you do a phase II," H.C. Wainwright & Co. analyst Corey Davis headlined his note assessing top-line data posted by Cara Therapeutics Inc. on its phase IIb trial of the oral formulation of its peripherally selective kappa opioid agonist, CR-845, in patients with osteoarthritis (OA) of the knee or hip. Read More

Mechanical mishap in midstage Aerosurf trial whips Windtree Therapeutics' shares

Clogged cartridge filters and the trial failure they likely caused battered shares of Windtree Therapeutics Inc. (OTCQB:WINT), sending the stock falling 61.8 percent Friday, or 53 cents, to close at 33 cents on news that its aerosolized medicine for preemies with respiratory distress syndrome, Aerosurf, failed to diminish the need for intubation, missing the trial's primary endpoint. Read More

Bench Press: BioWorld looks at translational medicine

Researchers from the International Mouse Phenotypic Consortium have published the comprehensive phenotypes of more than 3,300 knockout mice, describing mouse models for 360 diseases. Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 6, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for June 6, 2025.
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for June 3, 2025
  • Gilead Sciences divulges new compounds to treat herpes virus infection

    BioWorld Science
    Gilead Sciences Inc. has synthesized indoline compounds acting as DNA helicase-primase complex (human herpes simplex virus) and viral replication inhibitors...
  • Biotech deal illustration

    City hits the town with $1B-plus deal with Biogen

    BioWorld
    A development deal with Biogen Inc. could eventually bring City Therapeutics Inc. about $1 billion in milestone payments. It’s a step in the direction the company...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing

BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Biopharma M&A scorecard
    • BioWorld 2024 review
    • BioWorld MedTech 2024 review
    • BioWorld Science 2024 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Israel
    • Rise of obesity
    • Radiopharmaceuticals
    • Biosimilars
    • Aging
    • IVDs on the rise
    • Coronavirus
    • Artificial intelligence

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe